Condensed Consolidated Income Statement (unaudited) (USD $) In Thousands, except Per Share data	3 Months Ended		9 Months Ended		111 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011
Revenues:
Grant and contract revenues	$ 387	$ 484	$ 1,521	$ 1,512	$ 8,226
Total revenues	387	484	1,521	1,512	8,226
Operating Expenses:
Research and development	3,608	2,775	8,926	8,764	51,842
General and administrative	1,926	1,352	5,313	4,034	33,911
Total operating expenses	5,534	4,127	14,239	12,798	85,753
Other Income (Expense):
Interest income	21	35	64	73	1,755
Interest expense	(279)	(346)	(905)	(692)	(1,991)
Gain on derivative instruments	1,263	0	563	0	563
Total other income (expense)	1,005	(311)	(278)	(619)	327
Net loss	(4,142)	(3,954)	(12,996)	(11,905)	(77,200)
Beneficial conversion feature on Series 2008 preferred stock, conversion inducement and dividends on Series 1 preferred stock	0	0	0	0	(11,118)
Net loss attributable to common stockholders	$ (4,142)	$ (3,954)	$ (12,996)	$ (11,905)	$ (88,318)
Net loss per common share - basic and diluted	$ (0.04)	$ (0.05)	$ (0.13)	$ (0.15)
Weighted average common shares outstanding - basic and diluted	106,000	81,000	96,808	81,000